Parkinson Clinical Trial
Official title:
Treatment of Gait Disturbance in Parkinson's Disease With Prism Adaptation
NCT number | NCT02380859 |
Other study ID # | D15047 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 2015 |
Est. completion date | November 30, 2017 |
Verified date | March 2019 |
Source | Dartmouth-Hitchcock Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Subjects diagnosed with Idiopathic Parkinson's Disease, between ages of 40-85 inclusive, who have been referred for gait training. Since there can be subtle differences in the brain organization of left- and right-handed people that may influence some of the measurements, right handed participants are preferred. However, a left handed participant may be considered. Participants will be randomly assigned to one of two groups to undergo two weeks of twice-daily sessions. Group A receiving goggles fitted with lenses that distort vision and Group B patients receiving sham goggles
Status | Completed |
Enrollment | 32 |
Est. completion date | November 30, 2017 |
Est. primary completion date | July 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of idiopathic Parkinson's Disease - Referral for gait training - Aged 40 -85 - If the subject is taking CNS-acting medications (benzodiazepines, hypnotics, antidepressants), regimen must be stable for 30 days prior to baseline visit - Subjects with Stage 11.5 - Stage IV (Hoehn and Yahr scale) where stage II.5 is bilateral involvement with axial involvements, but without balance difficulty, to Stage IV where one has severe disability but is still able to walk or stand unassisted - Subjects with any of the following abnormal scores (greater than 0) in the MDS-UPDRS Part III; a) Part III.10 Gait; b) Part III.11 Freezing of gait c) Part III.12 Postural Stability; subjects with Timed up and go test >12 seconds - Right handed participants are preferred due to the cortical lateralization of functions related to sensorimotor adaptation and postural control. - However, we will recruit left-handed participants if there are insufficient right-handed volunteers. Exclusion Criteria: - Subjects with a known psychiatric comorbidity that in the investigator's opinion would compromise participation in the study; subjects with a neurologic diagnosis, other than Parkinson's disease that can cause imbalance and gait impairment (e.g., multiple sclerosis, stroke, subdural hematoma, peripheral neuropathy) - Injury or impairment to the right arm (other than that which is due to Parkinson's disease) that would affect pointing movements; subjects with normal score on UPDRS part III - Classified as legally blind or lacking sufficient visual acuity to view the target and pointing hand during prism adaptation - Lacking sufficient understanding of verbal and written information in English to complete any of the consent screening forms. |
Country | Name | City | State |
---|---|---|---|
United States | Darmouth-Hitchcock Medical Center | Lebanon | New Hampshire |
Lead Sponsor | Collaborator |
---|---|
Dartmouth-Hitchcock Medical Center | Michael J. Fox Foundation for Parkinson's Research |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Activities of Daily Living - New Freezing of Gait | Average change in score relating to new freezing of gate utilizing the New Freezing of Gait Questionnaire. This nine-item questionnaire detects and evaluates the impact and severity of freezing of gait on locomotion and daily activities. Items are scored from 0 or 1 to 3 or 4, with higher numbers indicating greater impact and severity. A total score out of 28 is calculated. | Baseline (Day 0) and Day 15 | |
Other | Change in Activities of Daily Living - Falls Efficiency | Average change in score evaluated using the Falls Efficiency Scale. This ten-item questionnaire asks people to rate their confidence in performing daily activities without falling. Responses are given on a scale from 0 ("very confident") to 10 ("not very confident") and a total score out of 100 is computed. | Baseline (Day 0) and Day 15 | |
Other | Change in Activities of Daily Living - Activity-specific Balance Confidence Scale | Activities-specific Balance Confidence Scale. This 16-item questionnaire is similar to the Falls Efficiency Scale, but has greater sensitivity to gait impairments in more ambulatory patients. Responses are given on a scale from 0 ("very confident") to 10 "not very confident") and a total score out of 100 is computed. | Baseline (Day 0) and Day 15 | |
Other | Change in Activities of Daily Living - Parkinson's Disease Questionnaire | Parkinson's Disease Questionnaire (PDQ-39), mobility and activities of daily living sections. This 39-item questionnaire is the most widely-used Parkinson's Disease specific measure of health and daily function. Participants indicate the extent to which they have experienced problems with different aspects of mobility and self-care. Each item is scored from 0 ("never have problems") to 4 ("always have problems"), and a percentage is calculated. In addition to the total score, the mobility (questions 1-10) and activities of daily living (questions 11-16) sub-sections can be analysed separately to assess changes in these specific outcomes. The responses are summed and scored as a percentage. We analysed the percentage scores for the mobility sub-section, the activities of daily living sub-section, and the total percentage. Higher values indicate worse outcome. | Baseline (Day 0) and Day 15 | |
Primary | Change in Postural Control - Reaction Time on the Limits of Stability Test (Smart Equitest Balance Master System) | The participant stood on the platform in front of a monitor. Nine squares were presented on the monitor representing locations relative to the upright starting position: one in the centre of the screen (upright) and the remaining eight forming an ellipse around the central square. The participant's COG was indicated on the screen by the position of a stick figure avatar. At the beginning of each trial the participant was instructed to stand upright, keeping the COG cursor over the central target. A circular target appeared in one of eight other targets. The participant was required to move the COG cursor towards the second target as quickly and as accurately as possible by leaning their body while keeping their feet in the same location, and to then hold a position as close to the target as possible. Reacting times were recorded for 8 trials per location. Mean change (post-pre) in seconds | Baseline (Day 0) and Day 15 | |
Primary | Change in Postural Control - Maximum Velocity on the Limits of Stability Test (Smart Equitest Balance Master System) | The participant stood on the platform in front of a monitor. Nine squares were presented on the monitor representing locations relative to the upright starting position: one in the centre of the screen (upright) and the remaining eight forming an ellipse around the central square. The participant's COG was indicated on the screen by the position of a stick figure avatar. At the beginning of each trial the participant was instructed to stand upright, keeping the COG cursor over the central target. A circular target appeared in one of eight other targets. The participant was required to move the COG cursor towards the second target as quickly and as accurately as possible by leaning their body while keeping their feet in the same location, and to then hold a position as close to the target as possible. Maximum velocity was recorded for 8 trials per location. | Baseline (Day 0) and Day 15 | |
Primary | Change in Postural Control - Maximum Extension on the Limits of Stability Test (Smart Equitest Balance Master System) | The participant stood on the platform in front of a monitor. Nine squares were presented on the monitor representing locations relative to the upright starting position: one in the centre of the screen (upright) and the remaining eight forming an ellipse around the central square. The participant's COG was indicated on the screen by the position of a stick figure avatar. At the beginning of each trial the participant was instructed to stand upright, keeping the COG cursor over the central target. A circular target appeared in one of eight other targets. The participant was required to move the COG cursor towards the second target as quickly and as accurately as possible by leaning their body while keeping their feet in the same location, and to then hold a position as close to the target as possible. Maximum extension of the COG over the feet was recorded for 8 trials per location. | Baseline (Day 0) and Day 15 | |
Primary | Change in Postural Control - Composite Score on the Sensory Organisation Test SMART EquiTest Balance Master | The participant is asked to maintain an upright posture under six different conditions of sensory feedback: Condition 1:Normal vision, fixed support Condition 2:Absent vision, fixed support Condition 3:Sway-referenced vision, fixed support Condition 4:Normal vision, sway-referenced support Condition 5:Absent vision, sway-referenced support Condition 6:Sway-referenced vision, sway-referenced support The equilibrium score for each condition compares the subject's anterior/posterior (AP) sway during each trial to the theoretical sway stability limit of 12.5 degrees. A composite equilibrium score (0-100, higher score indicates better outcome) quantifies the overall COG sway or postural stability across the sensory conditions and is calculated by: Independently averaging the score for conditions 1 and 2; Adding these two scores to the equilibrium scores from each trial of sensory conditions 3, 4, 5, and 6; and Dividing that sum by the total number of trials. |
Baseline (Day 0) and Day 15 | |
Primary | Change in Postural Control - Forward-backward Displacement of Centre of Gravity on the Sensory Organisation Test SMART EquiTest Balance Master | The participant is asked to maintain an upright posture under different conditions of sensory feedback. Proprioceptive feedback to the feet and joints is manipulated by allowing the platform to tilt to directly follow the participant's anteroposterior body sway (constant proprioception) or by maintaining the standing platform in a fixed horizontal position (normal proprioceptive feedback). Visual feedback is provided by asking the participant to close their eyes (no visual feedback), asking the participant to open their eyes and allowing the visual surround to tilt directly following the participant's anterioposterior body sway (constant visual feedback), or by asking the participant to keep their eyes open and maintaining the visual surround in a fixed position (normal visual feedback). Forward-backward displacement of COG is recorded in degrees. | Baseline (Day 0) and Day 15 | |
Primary | Change in Postural Control - Composite Latency Score on the Motor Control Test | The MCT assesses the ability of the automatic motor system to quickly recover following an unexpected external disturbance. Sequences of small, medium or large platform translations (scaled to the patient's height) in forward and backward directions elicit automatic postural responses. Translation of the surface in one horizontal direction results in displacement of the COG away from center in the opposite direction relative to the base of support. To restore normal balance, a quick movement of the COG back to the center position is required. A composite latency value is provided as the time in milliseconds between the force plate translation and the patient's active corrective responses, averaged across all translation sizes and directions. | Baseline (Day 0) and Day 15 | |
Primary | Change in Postural Control - Composite Latency Score on the Berg Balance Scale | Berg Balance Scale. This 14-item test assesses balance during different tasks. Items consist of specific items such as standing with eyes closed, retrieving an object from the floor, and turning to look behind. The assessor rates the patient's performance from 0 ("lowest level of function") to 4 ("highest level of function") and a total is calculated out of a maximum score of 56. | Baseline (Day 0) and Day 15 | |
Secondary | Change in Gait - Step Length on the Walk Across Test (SMART Equitest Balance Master) | The WA quantifies characteristics of gait as the patient walks across the length of the force plate. The test characterizes steady state gait by having the patient begin well behind and continuing beyond the force plate. Measured parameters are average step width, average step length, speed and step length symmetry. | Baseline (Day 0) and Day 15 | |
Secondary | Change in Gait - Step Speed in the Walk Across (SMART Equitest Balance Master) | The WA quantifies characteristics of gait as the patient walks across the length of the force plate. The test characterizes steady state gait by having the patient begin well behind and continuing beyond the force plate. Measured parameters are average step width, average step length, speed and step length symmetry. | Baseline (Day 0) and Day 15 | |
Secondary | Change in Gait - Timed Up and Go Task | Timed Up and Go Test (TUG). Patients are seated in a chair and instructed to stand up, walk three meters, turn around, walk back, and sit down. The time (in seconds) is recorded. | Baseline (Day 0) and Day 15 | |
Secondary | Change in Gait - Functional Gait Assessment | Functional Gait Assessment. This 10-item test assesses dynamic balance and postural stability during gait. Items consist of specific walking tasks such as stepping over an obstacle, changing speed of walking upon the assessor's instruction, and walking backwards. The assessor scores the patient's performance from 0 ("severe impairment") to 3 ("normal") and a total is calculated out of 30. | Baseline (Day 0) and Day 15 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06037590 -
A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops™ Relative to INBRIJA®
|
Phase 1 | |
Recruiting |
NCT01537224 -
Electrophysiological Activity of the Subthalamic Nucleus During the Processing of Emotional and Motivational Information
|
N/A | |
Withdrawn |
NCT04011449 -
State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S
|
N/A | |
Completed |
NCT02539446 -
Suprapostural Attention Focus and Postural Difficulty on H-reflex and Brain Activity: Aging and Parkinson's Disease
|
N/A | |
Completed |
NCT00358189 -
Effects of Deep Brain Stimulation for the Treatment of Parkinson's Disease
|
N/A | |
Active, not recruiting |
NCT04606979 -
tDCS of the Primary Motor Cortex to Improve Implicit Motor Sequence Learning in Parkinson's Disease
|
N/A | |
Completed |
NCT05119803 -
The Relationship of Spine Posture and Mobility With Upper Extremity Functions in Parkinson's Patients
|
||
Recruiting |
NCT06154772 -
Quality of Life, Anxiety and Fatigue Level of Parkison's Patients With Color Therapy
|
N/A | |
Not yet recruiting |
NCT02249715 -
Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease
|
N/A | |
Completed |
NCT01732653 -
A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults
|
N/A | |
Completed |
NCT03232996 -
Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.
|
N/A | |
Enrolling by invitation |
NCT04566341 -
Study of Gastrointestinal Dysfunction and Enteric Neural Pathology in Patients With Parkinson's Disease
|
||
Active, not recruiting |
NCT04978597 -
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)
|
Phase 3 | |
Recruiting |
NCT06116084 -
Randomized Controlled Study Evaluating the Efficacy of Hypnosis in Nuclear Medicine
|
N/A | |
Recruiting |
NCT05830396 -
GRoningen Early-PD Ambroxol Treatment
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05379062 -
Choral Singing for Patients With Parkinson's
|
N/A | |
Completed |
NCT02071823 -
Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules
|
Phase 1 | |
Recruiting |
NCT03558568 -
The Effect of Deep Brain Stimulation on Facial Expressions.
|
N/A | |
Enrolling by invitation |
NCT05596201 -
Super-resolution of Brain Magnetic Resonance Images in Deep Brain Stimulation for Parkinson's Disease
|
||
Recruiting |
NCT04181918 -
Action Observation Treatment in Parkinson's Patients
|
N/A |